Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 850501 | ISIN: US1101221083 | Ticker-Symbol: BRM
Tradegate
16.02.26 | 18:10
51,40 Euro
+0,53 % +0,27
Branche
Pharma
Aktienmarkt
S&P 100
S&P 500
1-Jahres-Chart
BRISTOL-MYERS SQUIBB COMPANY Chart 1 Jahr
5-Tage-Chart
BRISTOL-MYERS SQUIBB COMPANY 5-Tage-Chart
RealtimeGeldBriefZeit
51,0051,3819:40
51,0051,3818:58
ACCESS Newswire
406 Leser
Artikel bewerten:
(2)

Bristol-Myers Squibb Company: Bristol Myers Squibb and National Community Pharmacists Association Pilot Rural Heart Health Care Initiatives

BMS and NCPA to address cardiovascular disease and enhance patient care coordination with specialized training in rural Alabama, Arkansas, Kentucky, Louisiana, Mississippi, and Missouri pharmacies

Originally published on NCPA.org

NORTHAMPTON, MA / ACCESS Newswire / October 10, 2025 / Recently, Bristol Myers Squibb (NYSE: BMY) and the National Community Pharmacists Association (NCPA) announced a new collaboration aimed at improving heart health in rural communities in the United States.

NCPA has launched a program in partnership with BMS to address health-related social needs and care coordination for patients with cardiovascular disease (CVD) by piloting community health worker specialized training for pharmacy technicians. Pharmacist-community health worker teams in 25 rural pharmacies across Alabama, Arkansas, Kentucky, Louisiana, Mississippi and Missouri will be trained through a rigorous curriculum to more effectively evaluate patients with higher risk of CVD and guide them toward appropriate healthcare providers for further care and evaluation.

Additionally, NCPA is creating new access points at these same independent pharmacies for screening, monitoring and management of cardiovascular disease, funded through a separate and independent grant by BMS, as part of a pilot program to evaluate the impact of enhanced access to critical healthcare services in medically underserved communities.

CVD disproportionately impacts rural Americans, with adults in rural areas facing a 19% higher risk of developing heart failure and being 1.5 times more likely to die of CVD than adults in urban areas. Community pharmacies are often the only access point to connect patients with critical healthcare services in many rural geographies. BMS and NCPA's commitments to address healthcare disparities in rural America aim to improve healthcare delivery and, ultimately, outcomes.

"Too many patients in rural America face barriers to cardiovascular care-barriers that tragically cost lives," said Andrew Whitehead, vice president and head of Population Health at Bristol Myers Squibb. "Through our collaboration with NCPA, we are confronting these challenges head-on. By supporting the NCPA Community Health Worker training for pharmacy techs to further assist in the continuity of care for patients in these communities, we're helping to close a critical gap in our healthcare system and reaffirming our commitment to creating equitable access to care for all."

"We are pleased to partner with BMS to improve access to care for people in rural communities," said B. Douglas Hoey, pharmacist, MBA, CEO of NCPA. "The NCPA Innovation Center has partnered with the 25 rural pharmacies to improve cardiovascular outcomes through care coordination, screenings, transition of care interventions, and making sure patients have access to the medicines they need to sustain and improve health. Community pharmacists and their teams are increasingly playing a bigger role in the healthcare of Americans, and we are excited to create new, sustainable models of pharmacy-based care."

The National Community Pharmacists Association (NCPA) is a US-based organization that represents the interests of nearly 19,000 independent pharmacies across the country, many of which are located in areas where healthcare is hard to find, and one-third of which are in communities of less than 10,000 people.

###

View additional multimedia and more ESG storytelling from Bristol-Myers Squibb Company on 3blmedia.com.

Contact Info:
Spokesperson: Bristol-Myers Squibb Company
Website: https://www.3blmedia.com/profiles/bristol-myers-squibb-company
Email: info@3blmedia.com

SOURCE: Bristol-Myers Squibb Company



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bristol-myers-squibb-and-national-community-pharmacists-association-p-1085383

© 2025 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.